Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options

Katarzyna Drozda, Daniel J. Müller, Jeffrey R. Bishop

Research output: Contribution to journalReview articlepeer-review

57 Scopus citations

Abstract

Advancements in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice. Understanding how and when to use this technology to guide pharmacotherapy used to treat psychiatric and neurological (neuropsychiatric) conditions remains a challenge for many clinicians. Currently, guidelines exist to assist clinicians in the use of existing genetic information for drug selection and/or dosing for the tricyclic antidepressants, carbamazepine, and phenytoin. Additional language in the product labeling suggests that genetic information may also be useful for determining the starting and target doses, as well as drug interaction potential, for a number of other drugs. In this review, we outline the current status of pharmacogenomic testing for neuropsychiatric drugs as it pertains to information contained in drug labeling, consensus guidelines, and test panels, as well as considerations related to obtaining tests for patients.

Original languageEnglish (US)
Pages (from-to)166-184
Number of pages19
JournalPharmacotherapy
Volume34
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Keywords

  • Antidepressants
  • Antipsychotics
  • CYP2C19
  • CYP2D6
  • Pharmacogenetic testing
  • Pharmacogenetics
  • Pharmacogenomics
  • Stevens-Johnson syndrome

Fingerprint Dive into the research topics of 'Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options'. Together they form a unique fingerprint.

Cite this